Biocomposites Invests In Renovos Biologics - Developers Of The Renovite® Nanoclay Therapeutic Delivery Platform

Jul 05, 2023•over 2 years ago

SouthamptonHealth CareManufacturing

Investors

Biocomposites

Description

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces it has taken a minority-share interest in Renovos Biologics (Renovos), an innovative biologics company born out of research into the properties of nanoclay at the University of Southampton, UK. Michael Harris, CEO, Biocomposites will join Renovos Biologics Board of Directors.

Company Information

Company

Renovos Biologics

Location

Southampton, Pennsylvania, United States

About

Renovos is a regenerative medicine company and a specialist developer of RENOVITE® synthetic nanoclay for medical use. Stemming from research at the University of Southampton, UK, Renovos' proprietary RENOVITE® technology greatly improves the performance of a range of regenerative medicine products, with first targets in orthobiologics. RENOVITE® presents a novel mechanism of action, offering unprecedented retention of therapeutic agents at the target site of repair, mitigating their effects to a precisely controlled area, creating a step-change improvement in their efficacy, safety and ease of use, in biodegradable and injectable formulations, suitable for minimally-invasive applications.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns